Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has had recent discussions with his Danish counterpart on the cost-effectiveness of Orkambi in treating cystic fibrosis.

We have had no such discussions. The National Institute for Health and Care Excellence (NICE) assessed the cost benefit of Orkambi and was unable to recommend it. Vertex has been encouraged to engage in negotiations with NHS England and if it comes forward with a new proposal, NICE will be able to reconsider.